N/A
N=82
Role of Intravenous Versus Home Oral Antibiotics in Perforated Appendicitis
Perforated Appendicitis
Bottom Line
View on ClinicalTrials.gov: NCT02724410 ↗Enrolled (actual)
82
Serious AEs
2.4%
Results posted
Mar 2022
Primary outcome: Primary: Number of Participants With Postoperative Abscess — 5; 3 Participants — p=0.7188
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- home intravenous ertapenem (Drug); home oral amoxicillin-clavulanate (Drug); peripheral inserted central Catheter (Device)
- Age
- Pediatric · 4+ yrs
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Nov 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Postoperative Abscess |
5; 3 | 0.7188 |
| PRIMARY Number of Participants With Wound Infections |
1; 2 | .5933 |
| PRIMARY Number Participants With Readmission Within 30 Days |
6; 6 | >.99 |
| PRIMARY Hospital Charge |
47564.3; 34227.79 | <.0001 sig |
Summary
To compare the effect of a single-agent home intravenous (IV) versus oral antibiotic therapy on complication rates and resource utilization following appendectomy for perforated appendicitis
Eligibility Criteria
Inclusion Criteria
- Patients 4-17 years of age with perforated acute appendicitis diagnosed at time of appendectomy.
Exclusion Criteria
- Patients with a known severe allergy to penicillin (anaphylaxis), prior severe side effects from ertapenem or amoxicillin-clavulanate, pregnancy, or previous drainage procedure for abscess and/or fluid collection related to appendicitis.
Data sourced from ClinicalTrials.gov (NCT02724410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.